Previous 10 | Next 10 |
PALO ALTO, Calif. , April 30, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will participate and pr...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Gainers : Mustang Bio (NASDAQ: MBIO ) +117% . Checkpoint Therapeutics (NASDAQ: CKPT ) +19% . Amyris (NASDAQ: AMRS ) +18% . Uxin (NASDAQ: UXIN ) +17% . Viomi Technology (NASDAQ: VIOT ) +16% . Fortress Biotech (NASDAQ: FBIO ) +15% . Broadwind Energy (NASDAQ: BWEN ) +13% . Libbey (NYSE...
Mustang Bio ( MBIO ) - As I write this, shares have risen by over 300% after hours after the company announced that the New England Journal of Medicine had published data from St. Jude Children's Research Hospital regarding an early stage gene therapy trial. Specifically, the Phase 1/2 stud...
StoneCo (NASDAQ: STNE ) -15% . More news on: StoneCo Ltd., PagSeguro Digital Ltd., Reebonz Holding Limited, Stocks on the move, , Read more ...
Eiger BioPharmaceuticals (NASDAQ: EIGR ) has priced its public offering of 4.5M common shares at $11.00 per share, for gross proceeds of ~$49.5M. More news on: Eiger BioPharmaceuticals, Inc., Healthcare stocks news, Read more ...
PALO ALTO, Calif. , April 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share. All of the shares are being sold by...
PALO ALTO, Calif. , April 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering are to be sold by Eiger. In additi...
End-of-study post-treatment results from a Phase 2 clinical trial, LIMT HDV , evaluating Eiger BioPharmaceuticals' (NASDAQ: EIGR ) peginterferon lambda in patients with hepatitis D virus (HDV) infection showed a positive effect. The data were presented at The International Liver Congress ...
PALO ALTO, Calif. , April 11, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced end of study post-treatment results of the Phase 2 LIMT H...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...